Paroxetine CAS 61869-08-7 Health Care High Quality

Product Details
Customization: Available
Transport Package: Drum
Specification: 99%
Still deciding? Get samples of US$ 50/Piece
Request Sample
Diamond Member Since 2017

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Management System Certification
ISO 9001
Export Year
2016-08-01
Terms of Payment
LC, T/T, D/P, PayPal, Western Union, Small-amount payment, Money Gram, cash
  • Paroxetine CAS 61869-08-7 Health Care High Quality
  • Paroxetine CAS 61869-08-7 Health Care High Quality
  • Paroxetine CAS 61869-08-7 Health Care High Quality
  • Paroxetine CAS 61869-08-7 Health Care High Quality
  • Paroxetine CAS 61869-08-7 Health Care High Quality
  • Paroxetine CAS 61869-08-7 Health Care High Quality
Find Similar Products
  • Overview
  • Product Description
  • Detailed Photos
Overview

Basic Info.

Model NO.
61869-08-7
Trademark
PUYER
Origin
China
Production Capacity
10000kg/Month

Product Description

Product Description

 

Paroxetine, marketed under the brand name Paxil among others, is a selective serotonin reuptake inhibitor (SSRI) that is used to treat a variety of mental health conditions. It is primarily indicated for the management of major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder (PTSD), and the vasomotor symptoms of menopause. Additionally, it is used to treat premenstrual dysphoric disorder.

The drug works by increasing the levels of serotonin in the brain, which helps to improve mood and alleviate symptoms of the aforementioned conditions. Paroxetine is well tolerated by most patients, although it can cause side effects such as nausea, dizziness, dry mouth, sleep disturbances, and sexual dysfunction.

It is important to note that paroxetine has a boxed warning for an increased risk of suicidal thinking and behavior in children, adolescents, and young adults, especially during the initial few months of treatment. It also carries a warning for the potential development of serotonin syndrome, particularly when co-administered with other serotonergic drugs or within two weeks of stopping treatment with a monoamine oxidase inhibitor (MAOI).

Paroxetine has been associated with a withdrawal syndrome upon discontinuation, particularly when stopping the drug abruptly. Therefore, it is recommended to taper the dose gradually under medical supervision.

 

Detailed Photos
Paroxetine CAS 61869-08-7 Health Care High Quality

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier